Archrock Inc
Change company Symbol lookup
Select an option...
AROC Archrock Inc
PACK Ranpak Holdings Corp
NVEE NV5 Global Inc
YARIY Yara International ASA
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
SMHI SEACOR Marine Holdings Inc
ASC Ardmore Shipping Corp
Go

Energy : Energy Equipment & Services | Small Cap Value
Company profile

Archrock, Inc. is an energy infrastructure company with a pure-play focus on midstream natural gas compression. The Company is a provider of natural gas compression services to customers in the oil and natural gas industry throughout the United States, in terms of total compression fleet horsepower and a supplier of aftermarket services to customers that own compression equipment in the United States. The natural gas that it helps transport satisfies demand from electricity generation, heating and cooking and the industrial and manufacturing sectors. It has two segments. Its Contract Operations segment is comprised of its owned fleet of natural gas compression equipment that it uses to provide operations services to its customers. Its Aftermarket Services segment provides a full range of services to support the compression needs of its customers, which owns compression equipment, including operations, maintenance, overhaul and reconfiguration services and sales of parts and components.

Closing Price
$8.00
Day's Change
0.07 (0.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.13
Day's Low
7.90
Volume
(Heavy Day)
Volume:
1,308,672

10-day average volume:
1,011,290
1,308,672

Cerner Collaboration to Increase Access to Cancer Clinical Trials

2:15 pm ET May 18, 2022 (PR Newswire) Print

The company's Learning Health Network teams with Elligo Health Research and Freenome to Advance Early Cancer Detection

Cerner Corporation (NASDAQ: CERN), Elligo Health Research(R) and Freenome are collaborating to enable a clinical trial through the Learning Health Network to help advance early cancer detection. Together they will be using the research-activated network of health systems, real-world data (RWD) and multiomics technology, developed by Freenome, with the goal to help accelerate early cancer detection.

https://mma.prnewswire.com/media/1749045/Cerner_logo_Logo.jpg

This will be one of the first cancer screening trials available to Cerner's rapidly growing Learning Health Network (LHN), a group of more than 85 diverse health systems across the U.S., who are working together to help advance research and increase equitable access to clinical trials by contributing de-identified data. Trial participation will help LHN members bring innovative cancer prevention testing to the communities they serve - no matter their size or where they are located. Freenome, Cerner and Elligo will team up to use RWD to drive the Sanderson Study, an upcoming clinical trial to detect multiple types of cancer which is IRB approved and uses new multiomics technology.

Early cancer detection has been shown to not only increase survival rates, but earlier diagnosis can help lower treatment morbidity and improve quality of life -- for both patients and caregivers -- compared to later diagnosis. Other studies estimated significant cancer treatment cost savings from early detection, approximately $26 billion per year in the U.S.

Elligo Health Research, the largest healthcare-enabling research organization, will work with LHN members to accelerate site activation and enroll a large volume of diverse patients much faster than traditional recruitment models. Spanning the U.S., the collaboration will enable diverse patient participation, across a wide variety of demographics, socio-economic factors and all sizes of communities.

"The clinical research Cerner will enable has the potential to advance early cancer detection so patients can seek timely treatment and improve their chances of survival," said Christy Dueck, vice president, Cerner Enviza. "Data and technology have the power to help clinicians and researchers expand therapeutic knowledge and accelerate their development and delivery, which can improve people's lives around the world."

Freenome's multiomics platform combines both tumor and non-tumor signals with machine learning to detect cancer in its earliest, most treatable stages using a standard blood draw. Freenome, a privately held biotech company, is pioneering a patient-centric framework for multi-cancer early detection with single cancer and multi-cancer test baskets, using the same multiomics platform. This will more closely align with existing diagnostic care pathways to tailor future testing recommendations to individuals and optimize for clinical utility, reducing diagnostic odysseys.

"Our long-term goal is to advance multi-cancer products into clinical practice to save more lives," said Riley Ennis, chief product officer, Freenome. "This collaboration with Cerner and Elligo will enable us to generate real-world evidence and make our clinical studies available to more people, to save more lives."

"Faster clinical studies mean faster speed to market, which means more patients getting the medicine and technologies they need, sooner," said John Potthoff, Ph.D., CEO, Elligo. "Elligo's platform, together with Cerner's Learning Health Network, has the ability to significantly accelerate startup and engagement with thousands of patients for any study. We're thrilled to be part of this collaborative effort to advance important life-saving and life-changing early cancer detection technology."

About CernerCerner's health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers a connected clinical and financial ecosystem to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.com, Cerner Perspectives, connect on Facebook, Instagram, LinkedIn, Twitter or join the discussion on Cerner's podcast Perspectives on Health & Tech. Nasdaq: CERN.

About Elligo Health Research(R)Elligo Health Research accelerates clinical trials through healthcare with access to known patients and their HIPAA-compliant healthcare data, our IntElligo(R) Research Stack technology, and our hybrid enrollment model, PatientSelect. Coupled with the largest Known Patient Access Network, Elligo's Site Solutions enable healthcare practices and research sites to participate in clinical trials. By adaptive engagement of known patients and physicians, we accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.

About FreenomeFreenome is a biotechnology company with a comprehensive multiomics platform for the early detection of cancer using a blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California.

https://c212.net/c/img/favicon.png?sn=CG62343&sd=2022-05-18

View original content to download multimedia:https://www.prnewswire.com/news-releases/cerner-collaboration-to-increase-access-to-cancer-clinical-trials-301550472.html

SOURCE Cerner Corp.

https://rt.prnewswire.com/rt.gif?NewsItemId=CG62343&Transmission_Id=202205181415PR_NEWS_USPR_____CG62343&DateId=20220518

comtex tracking

COMTEX_407409409/1005/2022-05-18T14:15:06

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.